Clovis Oncology Inc (CLVS)

5.60 +0.02  +0.36% NASDAQ Mar 8, 10:16 USD
View Full Chart
Price Chart
View All CLVS News

News

View All Events

Events

Date Type Description
05/05/2021 Earnings Clovis Oncology Inc First Quarter Earnings Results for 2021
05/05/2021 Misc Clovis Oncology Inc First Quarter Earnings Conference Call for 2021
02/23/2021 Earnings Clovis Oncology Inc Fourth Quarter Earnings Result for 2020
02/23/2021 08:30 EST Misc Clovis Oncology Inc Fourth Quarter Earnings Conference Call for 2020
11/05/2020 Earnings Clovis Oncology Inc Third Quarter Earnings Result for 2020
11/05/2020 08:30 EST Misc Clovis Oncology Inc Third Quarter Earnings Conference Call for 2020
08/06/2020 16:30 EDT Misc Clovis Oncology Inc Second Quarter Earnings Conference Call for 2020
08/06/2020 Earnings Clovis Oncology Inc Second Quarter Earnings Result for 2020
06/04/2020 08:30 MDT Misc Clovis Oncology Inc Annual General Meeting for 2019
05/05/2020 16:30 EDT Misc Clovis Oncology Inc First Quarter Earnings Conference Call for 2020
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.clovisoncology.com
  • Investor Relations URL: http://phx.corporate-ir.net/phoenix.zhtml?c=247187&p=irol-IRHome
  • HQ State/Province: Colorado
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: May. 05, 2021
  • Last Earnings Release: Feb. 23, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.

Top Fund Holders

Symbol Name Weighting
XBI SPDR® S&P Biotech ETF 1.10%
LABU Direxion Daily S&P Biotech Bull 3X ETF 0.92%
F000013KMV ST Healthcare Innovations 7 F CA 0.78%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.